SAFETY AND EFFICACY OF AUTOLOGOUS DENDRITIC CELLS/TUMOR CELL ANTIGEN ADJUVANT THERAPY OF GLIOBLASTOMA MULTIFORME: RESULTS OF 59 CASES

A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414

INCREASING SURVIVAL IN BIOPSY-ONLY GBM PATIENTS

THE REPURPOSED CUSP9 REGIMEN EXERTS POTENT ANTI-NEOPLASTIC ACTIVITY AGAINST GLIOBLASTOMA CELLS IN VITRO

Bcl-2/Bcl-xL INHIBITION SYNERGISTICALLY ENHANCES THE ANTI-NEOPLASTIC ACTIVITY OF CUSP9 AGAINST GLIOBLASTOMA CELLS IN VITRO

IDO1 INCREASES Treg RECRUITMENT INDEPENDENT OF TRYPTOPHAN METABOLISM IN A MODEL OF GLIOBLASTOMA

A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY MAY PROLONG SURVIVAL FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR

ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA

IDENTIFYING THE GENETIC SIGNATURE OF RESPONSE IN A PHASE II STUDY OF TUMOR TREATING FIELDS IN RECURRENT GLIOBLASTOMA

HIGH-GRADE GLIOMA OUTCOMES IN THE PHASE 1 BXQ-350 TRIAL OF CANCER-SELECTIVE SapC-DOPS NANOVESICLES

THE EFFECT OF SELUMETINIB ON SPINAL NEUROFIBROMAS IN PATIENTS WITH NF1

INITIAL EXPERIENCE IN EPENDYMOMA WITH INVESTIGATIONAL CANCER-TARGETING BXQ-350 SapC-DOPS NANOVESICLES: A RARE TUMOR CASE STUDY

REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY